Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines (Q37100306)

18 August 2017

1 reference

title

Therapeutic advances in the prevention of hepatitis B: yeast-derived recombinant hepatitis B vaccines (English)

1 reference

18 August 2017

Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines (English)

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

5 December 2022

1 reference

M. W. Garrison

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1831578

5 December 2022

D. E. Baker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1831578

5 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1831578

5 December 2022

publication date

1 June 1991

1 reference

full work available at URL

18 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/106002809102500611

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

DICP : the annals of pharmacotherapy

5 December 2022

published in

1 reference

18 August 2017

25

1 reference

18 August 2017

617-627

1 reference

18 August 2017

6

1 reference

Hepatitis B infection in the United States. Recent trends and future strategies for control

18 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Hepatitis B: global importance and need for control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Familial Clustering of Hepatitis B Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

21 January 2018

Hepatitis B: the disease

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Development and production aspects of a recombinant yeast-derived hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Production and immunological analysis of recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Metastatic teratoma from a regressed impalpable testicular primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Hepatitis B vaccination of neonates and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Hepatitis B vaccines in patients with chronic renal failure before dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Temporary sequential atrioventricular pacing in myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Clinical experience with hepatitis B vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

The ventilatory response to hypoxia: how much is good for a mountaineer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500611

Current immunization practices. 2. Hemophilus influenzae, pneumococcal, and meningococcal infections, rabies, and hepatitis

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

5 December 2022

10

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients

5 December 2022

14

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

American journal of hospital pharmacy

5 December 2022

18

46

S14

Kapusnik-Uner JE

1989

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules

5 December 2022

33

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Genetic prediction of nonresponse to hepatitis B vaccine

5 December 2022

41

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Hepatitis B vaccine: low postvaccination immunity in hospital personnel given gluteal injections

5 December 2022

44

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Half-life of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination

5 December 2022

46

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients

5 December 2022

50

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

5 December 2022

51

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Exacerbation of eczema by formalin-containing hepatitis B vaccine in formaldehyde-allergic patient

5 December 2022

53

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

Vaccination against hepatitis B: comparison of three different vaccination schedules

5 December 2022

55

1 reference

https://api.crossref.org/works/10.1177/106002809102500611

5 December 2022

Identifiers

1 reference

18 August 2017

1 reference